Big pharma partnerships can boost home-grown type 2 diabetes drugs commercialization in China – The Pharma Letter
29-11-2022 Comments (0)Print27-09-202114-11-201612-11-201528-11-202228-11-202225-11-2022 The recent approval of Hua Medicine’s (HK: 2552) first-in-class diabetes drug – HuaTangNing (dorzagliatin tablets, HMS5552) – in China, in collaboration with Germany’s Bayer (BAYN: DE), puts…